Please login to the form below
tivozanib
This page shows the latest tivozanib news and features for those working in and with pharma, biotech and healthcare.
Aveo’s tivozanib is knocked back by FDA once again
Try as it might, Aveo Oncology just can’t persuade the FDA to accept a new regulatory filing for its kidney cancer candidate tivozanib. ... analysis at 263 events, and that the median OS for tivozanib is worse than that of sorafenib", notes Aveo.
Latest news
-
AVEO warns EU approval of Fotivda could be at risk
AVEO’s European licensee EUSA Pharma has been marketing Fotivda (tivozanib) for first- and second-line treatment of adults with renal cell carcinoma (RCC) since November 2017, after the EMA cleared
-
Daily Brief: Resignation throws Brexit into disarray, Celgene exec joins Orchard board, Scotland rules on EUSA drug
EUSA’s Fotivda approved for NHS use in Scotland. Specialist pharma company EUSA Pharma has welcomed the Scottish Medicines Consortium approval of its renal cell carcinoma treatment Fotivda (tivozanib).
-
NICE backs EUSA's RCC treatment Fotivda
The UK’s cost-effectiveness watchdog recommends its first-line use. EUSA Pharma has won NICE backing for Fotivda (tivozanib) as a first-line treatment for advanced renal cell carcimona (RCC).
-
EUSA receives European green light for kidney cancer treatment Fotivda
The trial showed that patients treated with tivozanib experienced superior progression-free survival verses sorafenib (11.9 versus 9.1 months). ... Patients on tivozanib also saw an improved side effect profile, with only 14% (versus 43% with sorafenib)
-
Samsung Bioepis wins CHMP nod for second Humira biosimilar
got the okay for VEGF receptor inhibitor Fotivda (tivozanib) for the treatment of advanced renal cell carcinoma. ... Tivozanib - originally developed by Aveo Pharma - was turned down by the FDA in 2013.
More from news
Approximately 4 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Deal Watch December 2015
405. Aveo (US). EUSA. Collaboration, licence. Pre-registration tivozanib for renal cell carcinoma.
-
Deal Watch table for November 2014
Acquisition of voucher. 125. AVEO Oncology / Ophthotech Corporation. VEGF tyrosine kinase inhibitor tivozanib.
-
Pharma deals during February 2014
In another termination of an oncology deal, Astellas exercised its right to terminate its collaboration with Aveo Oncology to develop the tyrosine kinase inhibitor, tivozanib, for “strategic reasons”.
-
Interview: Yoshihiko Hatanaka, CEO and president, Astellas
The company also has various in-licensing deals in the oncology space, including one concluded last year worth $1.4bn with Aveo Pharmaceuticals for tivozanib, which is currently being tested in
-
Interview: Ken Jones, Astellas Pharma Europe
We have also signed a deal with Basilea for Isavuconazole. In oncology, we've entered an agreement with AVEO Pharmaceuticals to commercialise and develop tivozanib, which has significant potential in a
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance
and oncology that we believe will be invaluable as we plan and advance our US registration strategy for tivozanib as a potential treatment for renal cell carcinoma.”.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
